Halloween Week 2025: U.S. Stock Market Rallies Amid Strong Tech Earnings -( $AAPL $AVGO $EPRX $INTC $LLY $NOK $NVDA $PLTR $RNA $TSLA Rise!)

By John F. Heerdink, Jr.

U.S. stocks wrapped up October with gains across most major indices, capped by Halloween’s close on Friday, October 31, 2025 and an ongoing U.S. Government shutdown. The S&P 500 ended the week higher by 0.71%, the Dow Jones Industrial Average advanced 0.75%, and the Nasdaq surged 2.24%, continuing a streak of resilient performance, while the Russell 2000 slipped 1.36% as small caps lagged.

Index Performance

S&P 500: Closed at 6,840.20, up 0.71% for the week, and seeing its third straight weekly advance, approaching all-time highs.
Dow Jones: Ended at 47,562.87, gaining 0.75% over the week.
Nasdaq: Finished at 23,724.96, jumping 2.24% as technology names outperformed.
Russell 2000: Fell to 2,479.38, posting a 1.36% weekly loss.

Interest rates & The FOMC

The Federal Reserve maintained a hawkish tone in its latest policy statement, cutting rates by a quarter point as expected, but cautioning about lingering inflation risks. The 2yr treasury closed the week at 3,584% rising post the meeting as did the 10yr closing at 4.083%. The next FOMC policy announcement is anticipated in late November.

Company-Specific Highlights

Eli Lilly (LLY): Rose sharply midweek, closing Thursday at $862.86 (+4.53%), boosted by encouraging drug pipeline updates.
Amazon’s (AMZN) third-quarter results delivered a thunderous beat over Wall Street’s expectations, driving a more than 13% surge in its share price after hours and confirming that its cloud and artificial intelligence investments are bearing fruit. The e-commerce and tech giant posted $180.2 billion in revenue—a 13% year-over-year rise—and adjusted earnings per share of $1.95, outpacing consensus forecasts by a sizable margin. The key growth engine: Amazon Web Services (AWS), whose revenue jumped 20% to $33 billion, its fastest pace in over a year, propelled by waves of enterprise demand for artificial intelligence capabilities and robust core infrastructure usage. This comes as the cloud space heats up, with AWS working to defend its lead as Microsoft and Google also post blockbuster cloud growth.
NVIDIA: Jumped, closing Tuesday up 8.71% over the last 5-days after strong quarterly results and announcing a slew of deals including the $1B deal with Nokia (NOK, $6.91, up +9.68% over the last 5-days) and propelling the firm close to a $5 trillion market cap milestone.
Apple: Posted robust fiscal Q4 earnings, driving the stock from $268.81 on Monday to $271.27 by week’s end; optimism for holiday sales.
Tesla: Saw volatility but finished at $456.5, up 5.27% over the last 5-days; investors responded to EV delivery and margin updates.
Broadcom: Rose from $362.05 on Monday to $369.63 by Friday, supported by chip sector momentum and positive guidance.
Meta: Dropped sharply after cautioning about higher 2026 expenses despite beating Q3 targets, falling from $750.82 on Monday to $646.35 by Friday.
McDonald’s: Traded down to $298.43, -2.41% over the last 5-days.
Rio Tinto: Modestly up for the week, closing at $71.74, +1.70%; global demand for metals steadied mining sector.
Oracle: Closed lower, with Friday’s close at $262.61 as software sector sentiment cooled after summer rally.
Intel: Consensus target price revised up; closed Friday at $39.99, +4.47% over the last 5-days.
Opendoor (OPEN): Closed at $7.77 and reports on Tuesday.
Palantir: Climbed 8.58% over the week, ending near $200.47.
Swiss pharmaceutical giant Novartis AG (NVS) has entered a definitive agreement to purchase Avidity Biosciences Inc. (RNA) for approximately $12 billion, a premium of 46% over Avidity’s most recent closing price. The acquisition, pricing shares at $72 each, marks one of Novartis’ largest deals in over a decade and signals an expanded commitment to high-impact rare disease treatments.

IPO

On the IPO front, the NYSE and Nasdaq saw a handful of deals, including a Dynamix Corporation III SPAC IPO and several smaller offerings. U.S. IPO volume for 2025 reached 297 by Halloween, up nearly 59% year-over-year, signaling robust capital markets activity.

Tariffs, Yield Curve, and Interest Rates

China and US made peace for the year with regard to tariffs. Oil retreated ahead of the OPEC+ meeting, gold closed above 4K/oz, and silver in the $48/oz range .

Vista Partners Watchlist Highlights & Updates

Eupraxia Pharmaceuticals (EPRX, $5.54, +1.28% over the last 5-days) is clinical-stage biotechnology firm headquartered in Victoria, Canada, that is leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need & has quietly become one of the more intriguing stories on both sides of the border in 2025. The company’s shares now trade under the ticker EPRX on both the Nasdaq and the Toronto Stock Exchange, following its U.S. market debut in April 2024. This dual listing has broadened its investor base at a time when the company’s clinical and financial narrative is gaining momentum. All covering analysts currently rate the stock as a “Buy” or better, with not a single “Hold” or “Sell” recommendation in sight. In a sector defined by binary outcomes and frequent disappointment, such unanimity is striking. Overall, analysts cite Eupraxia’s strong clinical pipeline and revenue growth potential as key drivers behind their bullish outlook.

View the Tribe Public event titled “How New Drug Delivery Methods Are Changing Lives: Eupraxia’s Innovations Explained.” This special event was co-hosted by James A. Helliwell M.D. the CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who will deliverer a brief presentation & was also be available for Q&A session.

After the close on Monday, Sept. 29, Eupraxia Pharmaceuticals provided an operational update on the development of EP-104GI, including reporting data from patients in Cohort 9 of the dose escalation portion of the RESOLVE trial, the first time that patients received an 8mg dose per injection. “We believe our recent financing, combined with our latest clinical trial results, underscores both the medical and investment communities’ confidence in EP-104GI. The strong efficacy trend observed in previous cohorts – the more drug we deliver to the tissue, the better the results we observe – has continued in Cohort 9. Combined with the absence of any Serious Adverse Events or cases of candidiasis, this strongly suggests that an 8mg dose per injection is the optimal second dose to test in our Phase 2b trial”, said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “We believe EP-104GI has the potential to significantly improve upon the current standard of care, as the clinical efficacy outcomes and improvements in tissue health reported so far are well beyond the published results for the leading currently approved therapies. With the capital raised, we are well-positioned to expand our Phase 2 study, prepare for a robust Phase 3 program, and pursue additional clinical indications, subject to discussions with FDA, all with a runway extending well into 2028”.

On Sept. 24 Eupraxia Pharmaceuticals announced the successful closing of its previously announced public offering (the “Offering”) of 14,636,363 common shares of the Company (the “Common Shares”), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$5.50 per Common Share for gross proceeds of approximately US$80.5 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering. “This financing represents a pivotal milestone for Eupraxia, enabling us to accelerate the development of EP-104GI for eosinophilic esophagitis and advance toward our upcoming Phase 2b clinical readout, plus other key clinical and regulatory milestones,” said James Helliwell, CEO of Eupraxia. “The strong participation from leading life-science focused investors validates both our strategy and technology, and with this financing, we believe we are now capitalized into the first quarter of 2028, providing the resources and flexibility to deliver on our vision.”

Cantor and LifeSci Capital acted as joint book-running managers for the Offering. Bloom Burton also acted as co-manager for the Offering.

Modular Medical, Inc. (NASDAQ: MODD, $.4949) is an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target the estimated $3 billion dollar adult “almost-pumpers” market with its user-friendly and affordable design. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

On October 30, GeoVax responded to testimony delivered at a Senate HELP Committee hearing by John Crowley, CEO of the Biotechnology Innovation Organization (BIO), who cautioned that U.S. biotech leadership could be overtaken by China within two years. GeoVax emphasized that Crowley’s warning should serve as a clear call to action for Congress and the Administration to secure America’s competitiveness and biosecurity through immediate investment and policy changes. GeoVax outlined six priority actions for policymakers:

Diversify vaccine platforms beyond reliance on mRNA, funding MVA and other multi-antigen, next-generation technologies.
Onshore advanced manufacturing with continuous cell-line vaccine production and U.S.-based fill/finish capacity.
Protect NIH funding that fuels the biotech innovation pipeline.
Modernize FDA pathways with expanded use of immuno-bridging and expedited programs for high-risk populations.
Expand incentives such as priority review vouchers for biodefense products.
Pair China guardrails with U.S. investment, ensuring scale-up and resilience at home.

On October, 28, Modular Medical announced that it is continuing to progress toward CE Mark certification under the European Union Medical Device Regulation (“EU MDR 2017/745”). As part of this process, the Company is pleased to announce the successful completion of its Stage 1 ISO 13485:2016 audit, conducted by BSI, its Notified Body and Registrar. The audit evaluated Modular Medical’s quality management system (“QMS”) for compliance with ISO 13485:2016 and alignment with EU MDR 2017/745 requirements, to confirm that the Company’s QMS is robust and well-documented, with no major nonconformances identified. “This milestone reflects the dedication of our team and our commitment to bringing innovative, patient-friendly, insulin delivery solutions to market in Europe and beyond,” stated Jeb Besser, CEO of Modular Medical. Completion of the Stage 1 audit paves the way for Modular Medical to advance to its Stage 2 audit in early 2026 – the final step before achieving the required ISO 13485 certification. In parallel, the Company will begin preparations for its CE technical documentation review under EU MDR 2017/745, which is anticipated to commence later in 2026. Successful completion of these steps is required for Modular Medical’s planned commercial launch in the European Union. The Pivot insulin delivery system is not currently cleared for sale by the U.S. Food and Drug Administration or in any other market outside the U.S.

On October 6, Modular Medical announced the appointment of David Bosshard as Head of International Operations. With two decades of expertise in scaling similar tubeless insulin delivery systems across Europe and beyond, Mr. Bosshard will drive Modular Medical’s global strategy, leveraging his success in launching blockbuster products, such as Insulet’s Omnipod and Ypsomed’s YpsoPump, to position the Company for international growth in the rapidly expanding wearable diabetes technology sector.

On Sept. 29, Modular Medical announced the exercise of certain existing warrants issued in May 2023 and March 2025 (the “Existing Warrants”) at a reduced exercise price of $0.68 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (file no. 333-271413), as amended, and Form S-3 (file no. 333-286768). In consideration for the immediate exercise of 6,504,731 Existing Warrants for cash, the Company will issue new unregistered warrants to purchase up to 3,252,366 shares of common stock (the “New Warrants”). The New Warrants will have an exercise price of $0.84 per share and will be exercisable upon issuance and will have a term equal to five years from the date of issuance. The gross proceeds to the Company from the exercise of the Existing Warrants were approximately $4.4 million, prior to deducting servicing agent fees and offering expenses. The Company intends to use the net proceeds for working capital and general corporate purposes.

On Sept. 15, Modular Medical announced Institutional Review Board (“IRB”) approval to conduct an in-house feasibility study of its next-generation Pivot insulin delivery system using sterile saline (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering sterile saline to adult participants for up to 90 days to gather critical data on device usability, extended wear performance and user feedback.

On September 11, Modular Medical announced the successful completion of a clinical study with the MODD1 pump. The MODD1 was worn by nine clinicians with Type 1diabetes who currently wear a continuous glucose monitor (“CGM”) and other pumps to provide the Company with real-world experience and feedback to make further refinements for the launch of its next-generation Pivot pump product. This MODD1 study was conducted to test and refine its ease of use for converting multiple daily injectors to this system and will continue as we prepare for the Pivot launch.

On August 26, Modular Medical announced that the MODD1 product cartridge production run has been completed and its manufacturing line is being converted to production for its Pivot product.“I want to congratulate our operational team for the successful validation of our MODD1 manufacturing process and production of human use cartridges,” said Jeb Besser, CEO of Modular Medical. “We will now begin converting our cartridge line to Pivot production, and we expect it to be ready to produce cartridges for our Pivot product upon receipt of clearance from the U.S. Food and Drug Administration (the “FDA”). We expect to submit the Pivot product to the FDA for clearance in October 2025. The Pivot will be the first tubeless, removable 3 milliliter patch to be available to the consumer when it is cleared. Along with these features, the ability to scale production is a key differentiator in the pump space, especially given the much higher volumes required for a patch pump. Modular Medical’s simple, low-cost platform was designed from the ground up for high volume manufacturing.”

Shares of ADT Inc. (ADT, $8.84, +.91% peer the last 5-days) is a leading provider of monitored security and automation solutions for residential and small business customers in the United States and Canada. On Sept. 30, ADT Inc. announced that its indirect wholly owned subsidiary, The ADT Security Corporation, has priced its offering of $1.0 billion aggregate principal amount of 5.875% first-priority senior secured notes due 2033 (the “Notes”) in an offering that will be exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) (the “Offering”).

GeoVax Labs, Inc. (Nasdaq: GOVX, $.5657), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, emphasized the urgent public health threat posed by the confirmation of locally transmitted Clade 1 Mpox cases in Los Angeles County, California. These cases represent the first known local spread of the more severe strain in the United States, underscoring the fragility of global vaccine supply chains and the critical need for second-source solutions. The U.S. remains reliant on a single, foreign manufacturer for the currently approved MVA-based mpox vaccine. This dependency creates vulnerabilities in cost, supply chain security, and surge capacity – at a time when outbreaks in Africa, Europe, and now the U.S. are escalating. “Relying on a single overseas manufacturer for such a critical biosecurity countermeasure is unwise and unsustainable,” said David Dodd, Chairman & CEO of GeoVax. “The emergence of locally spread Clade 1 mpox in California is a warning sign. America needs a diversified vaccine arsenal that includes U.S.-based manufacturing and scalable platforms designed for both epidemic response and national stockpiling.”

Diversify vaccine platforms beyond reliance on mRNA, funding MVA and other multi-antigen, next-generation technologies.
Onshore advanced manufacturing with continuous cell-line vaccine production and U.S.-based fill/finish capacity.
Protect NIH funding that fuels the biotech innovation pipeline.
Modernize FDA pathways with expanded use of immuno-bridging and expedited programs for high-risk populations.
Expand incentives such as priority review vouchers for biodefense products.
Pair China guardrails with U.S. investment, ensuring scale-up and resilience at home.

On October 29, GeoVax emphasized how its recently presented Phase 2 clinical data for GEO-CM04S1, first reported at the World Vaccine Congress Europe 2025, align with the new Infectious Diseases Society of America (IDSA) guidelines prioritizing vaccination for immunocompromised individuals. The IDSA guidance, issued October 17, 2025, concluded that existing COVID-19 vaccines provide only moderate and short-lived protection for immunocompromised patients – with effectiveness against hospitalization ranging from 33% to 56% and waning within two months. The panel called for new vaccine strategies tailored to vulnerable populations, including cancer patients, transplant recipients, and individuals receiving immunosuppressive therapies. “Immunocompromised Americans are not a niche,” said David A. Dodd, Chairman & CEO of GeoVax. “They are cancer patients, transplant recipients, people with autoimmune disease, and those living with HIV – one in eight adults. They include family members, colleagues and neighbors. Yet mainstream vaccine approaches, heavily centered on mRNA, continue to leave them without durable protection. The new IDSA guidelines reinforce the urgent need for alternatives like GeoVax’s GEO-CM04S1.”

On October 28, GeoVax highlighted the recently issued Infectious Diseases Society of America (IDSA) guidelines recommending immediate and prioritized COVID-19 vaccination for immunocompromised individuals. The new guidelines underscore the significant unmet need in this population – one that remains at heightened risk of severe illness despite widespread vaccine availability – and confirms what clinicians, patients and policymakers have long recognized: over 40 million Americans with weakened immune systems remain at heightened risk of severe COVID-19 illness and are underserved by existing vaccines.

On October 7, GeoVax Labs announced that its Chairman and CEO, David Dodd, will participate in the 4th Annual ROTH Healthcare Opportunities Conference, taking place on Thursday, October 9, 2025, at the Yale Club in New York City.

On Sept. 29, GeoVax Labs announced its strong support for the newly unveiled America First Global Health Strategy by U.S. Secretary of State Marco Rubio. The strategy underscores the importance of American innovation, domestic pharmaceutical manufacturing, and global partnerships in strengthening health security and safeguarding U.S. national interests.

Teladoc Health (TDOC, $8.63) is the world leader in virtual care. Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.

On Oct. 29, Teledoc reported financial results for the three months ended September 30, 2025 (“Third Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2024 (“Third Quarter 2024”). Teledoc highlighted:

Third Quarter 2025 revenue of $626.4 million, down 2% year-over-year
Third Quarter 2025 net loss of $49.5 million, or $0.28 per share
Third Quarter 2025 adjusted EBITDA of $69.9 million, down 16% year-over-year
Integrated Care segment revenue of $389.5 million, up 2% year-over-year, and adjusted EBITDA margin of 17.0%
BetterHelp segment revenue of $236.9 million, down 8% year-over-year, and adjusted EBITDA margin of 1.6%

On Oct.. 14, Teladoc Health announced the launch of a new offering to help hospitals and health systems address workplace violence. This is the latest innovation within Teladoc Health’s Clarity™ monitoring solution, which includes AI-enabled software, hardware and services that empower care teams to monitor care settings and quickly direct the right resources. The solution serves multiple use cases including virtual sitting and now virtual workplace safety intervention.

Serina Therapeutics, Inc. (NYSE American: SER, $5), is a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson’s disease, enabled by its proprietary POZ Platform™ drug optimization technology. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com.

On Oct. 8, Serina Therapeutics announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community.

On Oct. 6, Serina Therapeutics announced the drawdown of the first $5 million tranche from its previously announced financing agreement, which provides up to $20 million in funding upon achievement of defined development milestones. Proceeds will be used to advance the Company’s planned registrational trial of SER-252 for the treatment of advanced Parkinson’s disease.

On Sept. 10, Serina Therapeutics announced that it has entered into an agreement to access up to $20 million in financing led by Serina Board Director Greg Bailey, MD. The financing also includes the issuance of warrants which, if fully issued and exercised, could result in additional proceeds of up to $20 million. “This financing provides the resources to advance SER-252 through critical clinical milestones on the path toward registration,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “Importantly, the structure allows us to deploy capital in step with trial progress, while maintaining flexibility to access additional non-dilutive and strategic funding. We believe SER-252 has the potential to transform treatment for those with advanced Parkinson’s disease.”

On August 25, Serina Therapeutics announced that following a recent Type B meeting with the U.S. Food and Drug Administration (FDA), the FDA’s written feedback supports advancing SER-252 (POZ-apomorphine) in a registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathway. In its discussions with the FDA, Serina outlined a program designed to leverage prior knowledge of apomorphine utilizing the company’s POZ-enabled profile. Serina plans to include a pharmacokinetic (PK) bridging component to an approved apomorphine product, consistent with a 505(b)(2) NDA strategy. The FDA’s feedback indicates that Serina’s initial study may be designed and conducted as a component of a registrational trial program, subject to standard clinical and nonclinical requirements and finalization of documentation at the time of IND submission.

On August 11, Serina announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. Steve Ledger, CEO of Serina Therapeutics, stated, “We’re proud of the momentum we’ve built across our development programs. With SER-252 on track to enter the clinic later this year and the recent advancement of SER-270 for tardive dyskinesia, we are demonstrating how the POZ Platform can enable differentiated, long-acting therapies across neurological conditions with high unmet need. We believe our proprietary polymer technology can unlock best-in-class treatment profiles and improve patient outcomes in ways not achievable with existing drug delivery approaches.”

Amarin Corporation (NASDAQ: AMRN $16.29, a company that envisions a world where cardiovascular disease is NOT the leading cause of death worldwide, seemingly presents itself as a deep-value opportunity, trading near its cash value yet is believed to be poised for a turnaround driven by strategic shifts and international expansion. The company’s stock valuation currently reflects its liquidation value, but several catalysts suggest substantial upside potential as it retools its global strategy amid challenges in its core U.S. market.

On Oct. 29, Amarin announced financial results for the third quarter of 2025. Aaron Berg, President & CEO, Amarin stated, “With the reporting of Q3 2025 we usher in the next phase in the Amarin story. Our international commercial strategy is now a fully partnered model comprising seven parties and close to 100 countries with regional and in-country economies of scale, infrastructure and proven experience to commercialize a unique product like VASCEPA®/VAZKEPA® (icosapent ethyl). We are confident in the strategic actions we have taken at Amarin to date and optimistic about the potential of our global business. Meanwhile, we remain focused on additional ways to create value for shareholders. As always, we look forward to reporting on our future progress.”

On October 28, Amarin issued the following statement in response to the recent action taken by the U.S. Food and Drug Administration (FDA) to update the labeling for fenofibrate drugs in association with cardiovascular care:

We applaud the FDA’s decision to revise the labeling of fenofibrates (fibrates). The updated labeling now includes a clear statement on the lack of cardiovascular (CV) benefit, relevant safety data, and a refined indication as follows.

“Fenofibrate did not reduce cardiovascular disease morbidity or mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus.”

“Risk for rhabdomyolysis is increased when fibrates are co-administered with a statin. Avoid concomitant use unless the benefit of further alterations in TG levels is likely to outweigh the increased risk of this drug combination.”

“Fenofibrates are now indicated for the reduction in elevated LDL-C in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible.”

InterGroup Corporation (INTG, $36.59) recently reported marked financial improvement for the fiscal year ended June 30, 2025, with strengthened core business results and a substantial rebound in its liquidity position, while returning to compliance with Nasdaq listing requirements.

M2i Global, Inc. (MTWO, $.1025), through its subsidiary U.S. Minerals and Metals Corp., provides engineering, research, and services that integrate people, technology, and solutions from across sectors to ensure access to critical minerals and metals for national defense and economic security. M2i Global aims to establish a Strategic Mineral Reserve in partnership with the U.S. Federal Government, creating a resilient supply chain that addresses the global shortage of essential minerals and metals. For more information, please visit: www.m2i.global.

On July 29, 2025, Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven private aviation company and M2i Global, Inc. (“M2i Global”) (OTCQB: MTWO), a company specializing in the development and execution of a complete global value supply chain for critical minerals, announced the signing of a definitive business combination agreement in which Volato will acquire 100% of the issued and outstanding shares of common and preferred stock of M2i Global. The proposed transaction was previously announced on June 12, 2025 following the signing of a non-binding letter of intent.

Nokia Corporation (NOK, $6.91, +9.68% YTD) recently reported strong Q3 earnings, showcasing 12% year-over-year revenue growth. The company is expanding its partnerships and developing new technologies for the 6G era, while also seeing positive movements in analyst sentiments regarding its future prospects. As a B2B technology innovation leader, Nokia is pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, they create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs, which is celebrating 100 years of innovation. With truly open architectures that seamlessly integrate into any ecosystem, their high-performance networks create new opportunities for monetization and scale. Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks today – and work with them to create the digital services and applications of the future.

Nokia (NOK) has returned to the global spotlight with strategic maneuvers that point toward a revitalized growth narrative, highlighted by today’s announcement that Nvidia will invest $1 billion for a 2.9% equity stake in the Finnish telecom titan. This is more than a landmark capital infusion—it sets the stage for Nokia’s network software to run on Nvidia’s architecture and positions the company squarely at the intersection of telecom and the AI-powered data center market, an axis coveted by both investors and industry peers.

Quote of The Day

“I love the spirit of Halloween and the energy that comes with it.” –

Katharine McPhee

Sources

Investing & Inspiration

Post View Count : 501

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

We value your privacy and will never share your information.